Compare VanEck Gold Miners ETF (GDX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs IDEXX Laboratories, Inc. — how do they compare? VanEck Gold Miners ETF trades at $89.28 (market cap $25.65B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and VanEck Gold Miners ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| GDX | IDXX | |
|---|---|---|
Market Cap | $25.65B | $40.43B |
Volume | 16,534,046 | 692,164 |
52-Week High | $115.84 | $766.68 |
52-Week Low | $68.28 | $504.70 |
Typical Hold Time | 76 Days | 46 Days |
Sector | — | Health |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX (VanEck Gold Miners ETF) trades at $86.74, up 1.5% on the day but facing bearish technical signals with 15 sell indicators versus 4 buy signals. The ETF remains 22% below its peak despite gold trading near $4,270, creating a potential catch-up opportunity. Recent institutional activity shows mixed sentiment with some firms reducing positions while others increased stakes significantly.
The outlook remains cautious with technical indicators pointing bearish, though gold's resilience amid rising rates provides fundamental support. Key risks include interest rate sensitivity and metals price volatility, while the valuation gap between physical gold and miners presents a potential opportunity if gold maintains strength.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
